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BACKGROUND: Interleukin-1 (IL-1), an inflammatory
cytokine whose levels are elevated in inflamed mu-
cosa, causes part of its effect on intestinal epithelial
cells (IEC) through inducing ceramide production.
Aim: To study the role of nuclear factor-kB (NF-kB), a
pro-inflammatory and anti-apoptotic factor, in IL-1-
treated IEC.
Methods:N F - kB activity and levels of apoptotic
proteins were assessed by electrophoretic mobility
shift assay and RNA-protection assay, respectively.
Results: IL-1 and ceramide, which have been shown
to partially mediate IL-l effects on IEC, activated NF-
kB levels significantly. This activation was due to a
decrease in IkB-a and IkB-b protein levels. Moreover,
the ratio of mRNA levels of anti-apoptotic to pro-
apoptotic proteins was significantly increased in IL-1-
treated IEC.
Conclusion:N F - kB may play a key role in the
regulation of the expression of pro-inflammatory
and/or apoptotic genes in inflammatory bowel dis-
ease, making this protein an attractive target for
therapeutic intervention.
Key words: Nuclear factor-kB, Interleukin-1, Inﬂamma-
tory bowel disease, Inﬂammation, Intestinal epithelial cells
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Introduction
Transcriptional factors of the nuclear factor (NF)-kB/
Rel family regulate the expression of genes involved
in inflammation, cell proliferation and apoptosis.
1,2
NF-kB is rapidly activated in response to a wide
variety of stimuli such as viral and bacterial infections
or the interaction of the inflammatory cytokines with
their receptors.
3 It is a heterodimer of the p50 (NF-
kB-l) and p65 (Rel-A) subunits; however, proteins
that constitute the NF-kB family form a variety of
functional homodimers and heterodimers.
4 6 Under
resting conditions, the complex is present in the
cytoplasm sequestered in an inactive form due to its
association with an inhibitory protein belonging to
the IkB family. Activation of NF-kB involves the
dissociation of the Rel-A subunit from the inhibitory
proteins, such as IkB-a, and the translocation of Rel-A
from the cytoplasm to the nucleus, where it dimerizes
with the p50 or c-Rel subunits and interacts with
specific target genes.
7 The dissociation of Rel-A from
IkB occurs following a cascade of intracellular events
that leads to specific phosphorylation of the inhibi-
tory subunit
7 on serine or tyrosine residues.
8,9 This
phosphorylation is follwed by ubiquitination and
proteolysis of the inhibitory protein via a non-
lysosomal, adenosine triphosphate (ATP)-dependent
proteolytic proteasome. Inflammatory cytokines such
as tumor necrosis factor (TNF)-a and interleukin-1
(IL-1) have been shown to be elevated in the mucosa
of patients with inflammatory bowel disease. These
cytokines possess diverse biological functions that
include cell proliferation, inflammation and apopto-
sis. They contribute to activation of intestinal epithe-
lial cells (IEC) activation as well as the activation of
immune cells that get recruited after the inflammatory
insult. We have shown that in IEC, IL-1 activates
sphingomyelinase, an enzyme that catalyzes the
hydrolysis of sphingomyelin to ceramide.
10 In con-
trast to what has been observed in many cell types,
however, ceramide did not induce apoptosis in IEC,
neither did IL-l, but rather induced the synthesis of
cyclooxygenase-2 (COX-2) leading to increased le-
vels of pro-inflammatory mediators such as prosta-
glandin E2.
11 NF-kB consensus regions have been
shown to be present on the COX-2 promoter region
and these regions have been shown to be involved in
COX-2 mRNA induction by cytokines.
12 Moreover,
NF-kB seems to possess a significant anti-apoptotic
role.
13,14 Indeed, some known pro-apoptotic extra-
cellular signals can induce NF-kB that in turn induces
the expression of genes that are anti-apoptotic.
14
Mediators that can induce NF-kB could therefore
protect against apoptotic elimination of affected cells.
Interestingly, this anti-apoptotic role of NF-kB has
only been described for Rel-A but not for c-Rel or
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277In this study we investigate the effects and
mechanism of action of IL-1 and/or ceramide in
regulating NF-kB in IEC. Activation of NF-kB by IL-1
may be responsible for the lack of apoptosis ob-




Human recombinant IL-1a was obtained from Im-
munex (Seattle, Washington, USA). Bromophenol
blue, coomassie blue R-250, alkaline phosphatase-
conjugated goat anti-rabbit IgG, polyvinylidene di-
fluoride (PVDF) membrane, sodium dodecyl sulfate
(SDS), glycine tris, glycerol, 2-b-mercaptoethanol,
and g-
32P ATP were from Amersham Pharmacia
Biotech (UK). Fetal bovine serum albumin and
bovine serum albumin, penicillin and streptomycin,
Dulbecco’s Modified Eagle’s Medium (DMEM), pyr-
uvate, non-essential amino acids, goat serum and
Earl’s balanced salt solution were from Gibco La-
boratories (Invitrogen, Carlsbad, California, USA).
Acrylamide and N?, N?-bis-methylene-acrylamide
were from BioRad (California, USA), ammonium
persulfate, N,N,N?,N?, Tetramethylethylenediamine
(TEMED), chloroform, ethylenediamine tetraacetic
acid (EDTA), Ethylene glycol-bis-(2-aminoethyl)-
N,N,N?,N?-tetraacetic acid (EGTA), methanol, acetic
acid, isopropanol, dithiothreitol, imidazole, LiCl, and
etoposide were from Sigma (St Louis, Missouri, USA).
N-acetyl sphingosine (C2 ceramide) and ZLL (Z-leu-
leu-leu-CHO), a proteasome inhibitor, were pur-
chased from BioMol (Plymouth Meeting, Pennsylva-
nia, USA). RNA protection Kits and templates were
obtained from BD Pharminegen (San Diego, Califor-
nia, USA). The multi-probe RPA template mapo-2
was used and it contained probes for the following
mRNA: anti-apoptotic proteins bcl-2, bcl-w and
bcl-xl, and pro-apoptotic proteins bad, bax, bak
and bfl-1, and the housekeeping genes L-32 and
GAPDH.
Antisera
Rabbit polyclonal antisera to IkB-a,I kB-b, c-Rel, Rel-
A, NF-kB p50, NF-kB consensus oligonucleotide,
luminol reagents, ECL marker and anti-rabbit 1gG
horseradish peroxidase (HRP)-conjugate subunit
were purchased from Santa Cruz Biotechnology
(Santa Cruz, California, USA).
Methods
Cell culture
Murine intestinal epithelial cell 1ine Mode-K
16 was
obtained from Dr P.B. Ernst (University of Texas,
Medical Branch, Galveston, Texas, USA). Mode-K
cells were maintained in DMEM (low glucose)
containing 10% fetal bovine serum (FBS), 10 mM
sodium pyruvate, and non-essential amino acids. T-
84 cells, human colonic cell line, were grown in
DMEM/F-12 medium supplemented with 10% FBS.
Cell viability was measured using the trypan blue
exclusion assay.
Preparation of homogenate. Cells were trypsi-
nized, centrifuged at 200 g, and washed in phos-
phate-buffered saline (PBS) twice. The cells were
then resuspended in PBS: 2 /electrophoresis sample
buffer (SB), ratio 1:1. The sample buffer consisted of
0.25 M Tris /HCl (pH 6.8), 4% w/v SDS, 20% v/v
glycerol and 0.1% bromophenol blue. Samples were
then boiled for 5 min and stored at  /808C.
Nuclear extract preparation
Cells were harvested and collected by centrifugation
at 200 g for 10 min and washed once with PBS. Cells
were lysed by rapid freezing in ethanol/dry ice and
thawed by resuspension in a hypotonic ice-cold
buffer containing 10 mM KCl, 1.5 mM MgCl2,1m M
dithiothreitol (DTT), and 10 mM Hepes. The nuclei
were centrifuged at 1250 g for 10 min at 48C and the
nuclear pellets were gently extracted in a hypertonic
solution containing 0.4 mM NaCl, 1.5 mM MgCl2,0 . 2
mM EDTA, 1 mM DTT, 0.5 mM PMSF, 20 mM Hepes
and 25% glycerol, for 30 min at 48C, and then
centrifuged for 20 min at 20,000 g to collect the
nuclear proteins in the supernatant. The supernatant
was diluted with 30 ml of buffer containing: 50 mM
KCl, 20% (v/v) glycerol, 0.2 mM EDTA, 1 mM DTT,
0.5 mM PMSF and 20 mM Hepes, and stored at
 /708C. Protein concentrations were determined
using the Bio-Rad assay.
Western blotting
Total protein extracts were run on a 12% SDS-
polyacrylamide gels. Gels were transferred to PVDF
membranes overnight at 48C. Following transfer,
membranes were washed with PBS containing 0.1%
Tween 20 (TPBS) and blocked with 5% non-fat dry
milk for 1 h at room temperature. Antibodies were
then added in TPBS and incubated for 2 h at room
temperature. Unbound antibodies were washed three
times with TPBS and the anti-rabbit IgG HRP-
conjugate was added at 1:5000 dilution for 1 h at
room temperature. The membranes were washed
and incubated with luminol reagents and then
exposed to autoradiography.
Electrophoretic mobility shift assay
NF-kB consensus oligonucleotide was end-labeled
with g-
32P ATP using T4 polynucleotide kinase. The
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mg of nuclear extract, 1 mg of poly(dI.dC), 1 mgo f
poly(dN6) as a non-specific competitor, and 10 mgo f
bovine serum albumin in 20 mM Hepes, 50 mM KCl,
1 mM EDTA and 5 mM DTT. The reaction was diluted
with water to a v/v ratio of 1:20 of the labeled probe.
The mixture was incubated for 30 min, then stopped
by adding 6 ml of 15% Ficoll solution containing the
indicator dyes bromophenol blue and xylene cyanol.
The reaction mixture (20 ml of each sample) was
electrophorized on a 5% non-denaturating polyacry-
lamide gel. The gel was transferred to Whatman filter
paper, dried at 808C under vacuum for 2 h and
processed for autoradiography at  /808C overnight.
The specific NF-kB band was determined by compe-
tition experiments using a mutant oligonucleotide
that has lost its ability to bind to the transcription
factor. Subunit specificity was determined using
specific antibodies to the NF-kB components (anti
Rel-A, p50 and c-Rel) in the incubation step, which
results in a supershift of the specific band due to the
bound antibody.
RNase protection assay
Radioactive RNA probes were synthesized from DNA
templates using T7 RNA polymerase and radioactive
UTP as a substrate. The reaction was terminated after
1 h incubation at room temperature by the addition
of DNase. The labeled RNA probes were extracted
once with phenol:chloroform-isoamyl alcohol and
once with chloroform-isoamyl alcohol. The probes
were then precipitated in equal volume of 4 M
ammonium acetate and 5 volumes of ice-cold abso-
lute ethanol, incubated at  /808C for 30 min,
centrifuged at full speed for 15 min at 48Ci na
microcentrifuge, washed once with 90% ethanol,
allowed to air-dry and then solubilized in hybridiza-
tion buffer and quantified using a scintillation
counter. RNA samples (2 /20 mg) were dried
under vacuum and hybridized with the probe over-
night.
Unhybridized RNA were digested using RNase A
and the reaction was terminated by the addition of
Proteinase K. Hybridized RNA were then extracted
using phenol:chloroform-isoamyl alcohol, precipi-
tated in ammonium acetate and absolute ethanol,
washed once with 90% ethanol and then air-dried.
The pellets were solubilized in loading buffer (sup-
plied by the manufacturer) and were ran on a 5%
acrylamide-urea gel using 0.5 /tris borate /EDTA
buffer (containing 45 mM tris-borate, and 1 mM
EDTA, pH 8.0) as a running buffer, dried and exposed
to autoradiography. Yeast tRNA was used as a
negative control.
Results
IL-1 targets the NF-kB pathway
To establish whether IEC are functionally coupled to
biological signals that lead to the activation of NF-kB
by IL-1, cells were treated with IL-1 at different
concentrations and time periods, and the NF-kB
DNA binding activity was measured in nuclear
extracts by eletrophoretic mobility shift assay using
a NF-kB consensus oligonucleotide. We first con-
firmed the constitutive expression of NF-kB in Mode-
K cells. Two positive complexes were detected by the
radiolabeled NF-kB consensus oligonucleotide (Fig.
1). These complexes were not changed in the
presence of a mutant oligonucleotide (data not
shown).
IL-1 has been shown to activate the sphingomyelin
metabolic pathway, which will cause increased
accumulation of ceramide in IEC.
10 Ceramide acts
as a second messenger in IEC and seems to mediate,
at least in part, the effects of IL-l observed on IEC
function. Thus the effect of ceramide on NF-kB in the
presence or absence of IL-l was tested. Treatment of
IEC by IL-l and/or ceramide caused a significant
increase in NF-kB levels in Mode-K cells (Fig. 2).
Supershift assays using anti-p50 and c-Rel-specific
antibodies showed little variation in the amount of
the DNA-bound proteins with the various treatments,
while Rel-A-containing heterodimers (activated NF-
kB state) were supershifted, indicating that Rel-A is
the major subunit that is translocated to the nucleus
after cell activation by IL-1.
Regulation of IkB subunits by IL-1
Effect of IL-1 and ceramide on IkBa protein
levels
We next examined the effect of IL-1 on the activation
of IkB to determine which subunit is responsible for
FIG. 1. Constitutive expression of NF-kB in Mode-K cells. In
the second and third lane, as indicated, are shown increased
expression of NF-kB in IL-1-treated cells (10 ng/ml and 30 ng/
ml, respectively) for 24 h. In the last two lanes are shown
increased expression of NF-kB in ceramide-treated cells (10
and 30 mM, respectively) for 24h. Equivalent amounts of
nuclear extract from IEC were prepared and analyzed for NF-
kB binding activity with a
32P-labeled oligonucleotide probe
containing NF-kB binding sites. This experiment is repre-
sentative of six.
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different IEC lines, Mode-K and T-84 (Figs. 3 and 4,
respectively). The decrease in IkB levels releases Rel-
A and allows its translocation. IL-1 and ceramide
caused a significant decrease in IkBa levels (both
time and concentration dependent) with a significant
decrease occurring at around 4 h with both treat-
ments.
Effect of IL-1 and ceramide on IkBb protein
levels
IL-1 and ceramide also induced a decrease in the
levels of IkBb levels in T-84 cells. The decrease,
which was time (Fig. 5) and concentration dependent
(data not shown), was maximal around 1 h with both
treatments. The decrease observed in the levels of
IkBa that was maximal at 4 h for IL-1 (10 ng/nl) and
ceramide (10 mM) was much greater than that
observed with Ik-Bb for the same treatment (80%
decrease at 4 h versus 40% at 1 h in ceramide-treated
cells, for example). This suggests that both IkBa and
IkBb may be involved in releasing NF-kB from the
cytosolic complex to translocate into the nucleus;
however, the effect of treatment on IkBb proceeds
that of IkBa. Similar results were obtained in Mode-K
cells (data not shown).
Effects of IL-1 and ceramide on IkBo protein
levels
The effect of ceramide and/or IL-1 on IkBo were also
investigated. Neither treatment had any significant
effect on the levels of IkBo (for Mode-K cells tested
up to 24 h; Fig. 6) in either IEC line used, suggesting
that it is not involved in the action of IL-1 on NF-kB
activation.
FIG. 2. Regulation of NF-kB activity by IL-1 and ceramide in
IEC. Treatment of IEC by IL-1 and ceramide individually or in
combination caused a signiﬁcant increase in NF-kB levels in
Mode-K cells. Supershift analysis of nuclear extract from
cells incubated with rabbit antibody directed towards the p65
subunit (lane 10) or p50 subunit (lane 11) of NF-kB.
Equivalent amounts of nuclear extract from IEC were
prepared and analyzed for NF-kB binding activity with a
32P-labeled oligonucleotide probe containing NF-kB binding
sites. Supershift assays using anti-p50-speciﬁc antibodies
showed little but signiﬁcant variation in the amount of the
DNA-bound proteins, while Rel-A containing heterodimers
(activated NF-kB state) were greatly supershifted, indicating
that Rel-A is the major subunit that is translocated to the
nucleus after cell activation by IL-1.
FIG. 3. Inhibition of IkBa levels by IL-1 (30 ng/ml) treatment
for different time periods in Mode-K cells using western blot
analysis of cytoplasmic extracts from IL-1-treated IEC. Ex-
pression of IkBa was visualized using IkB-a-speciﬁc poly-
clonal antibody. To conﬁrm equal protein loading the
membrane was stripped and reprobed with actin antibody.
The bands were quantiﬁed using the Molecular Dynamics
Storm 860 System (Molecular Dynamics, Sunnyvale, Cali-
fornia, USA) using ImageQuant software. The density of the
band equivalent to IkBa levels in control untreated cells was
set at 100% and the rest of the bands were calculated as a
percentage of the control. *pB/0.05, **pB/0.005; p value
represents the comparison of the effect of IL-1 on IkBa levels
as compared with untreated control (n /4).
FIG. 4. Inhibition of IkBa levels by IL-1 (30 ng/ml) and
ceramide (10 mM) treatment for different time periods in T-
84 cells using western blot analysis of cytoplasmic extracts
from IL-1-treated and/or ceramide-treated IEC. Expression of
IkBa was visualized using IkBa-speciﬁc polyclonal antibody.
To conﬁrm equal protein loading the membrane was
stripped and reprobed with actin antibody. The bands were
quantiﬁed using the Molecular Dynamics Storm 860 System
(Molecular Dynamics) using ImageQuant software. The
density of the band equivalent to IkBa levels in control
untreated cells was set at 100% and the rest of the bands
were calculated as a percentage of the control. *pB/0.05,
**pB/0.005; p value represents the comparison of the effect
of IL-1 on IkBb levels as compared with untreated control
(n /4).
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protein levels in the presence of ZLL
ZLL is a potent and selective reversible proteasome
inhibitor. It inhibits NF-kB activation by preventing
IkB degradation. Cells were treated with ZLL for
different time periods before IL-1 or ceramide treat-
ment, and the levels of IkBa and IkBb were
measured (Fig. 6). ZLL reversed the effect induced
by IL-1 or ceramide on both IkB levels, thus
preventing their degradation, and subsequently no
translocation of NF-kB was observed. These data
suggest therefore that translocation of NF-kBi s
dependent on the activation of proteasome that leads
to the degradation of IkBa and IkBb, thus freeing NF-
kB to translocate to the nucleus for its action on
activating different genes.
Regulation of mRNA levels of apoptotic proteins
by IL-1 treatment
Using the RNA protection assay, the mRNA levels of
apoptotic proteins were shown to be regulated by IL-
1 treatment. The mRNA levels of the anti-apoptotic
proteins bcl-x and blc-w were increased while bcl-2
was unchanged; and the levels of the pro-apoptotic
proteins bax, bak and bad were significantly reduced
(Fig. 7). Similar results were obtained when cells
were treated with ceramide. These data provide
supportive evidence that IL-1 and/or ceramide do
not induce apoptosis in intestinal epithelial cells and,
rather, they feed into the prostanoid synthetic path-
way through the induction of COX-2.
11
Discussion
Apoptosis is a highly conserved evolutionary event
crucial for normal development and homeostasis.
Deregulated cell death has been associated with
disease entities such as cancer
17 and cardiovascular
disease.
18 Cells defective for NF-kB signaling were
found to be more sensitive to apoptotic-inducing
signals than normal wild-type cells,
19,20 suggesting an
anti-apoptotic role for NF-kB. NF-kB is a transcription
factor involved in the regulation of many genes and is
activated in response to a wide variety of stimuli
including inflammation, viral and bacterial infections
FIG. 5. Inhibition of IL-1 on IkBb levels by IL-1 (30 ng/ml) and
ceramide (10 mM) treatment in T-84 cells. Westem blot
analysis of cytoplasmic extracts from IL-1-treated and/or
ceramide-treated IEC. Expression of IkBb was visualized
using IkBb-speciﬁc polyclonal antibody. To conﬁrm equal
protein loading the membrane was stripped and reprobed
with actin antibody. The bands were quantiﬁed using the
Molecular Dynamics Storm 860 System (Molecular Dy-
namics) using ImageQuant software. The density of the
band equivalent to IkBa levels in control untreated cells
was set at 100% and the rest of the bands were calculated as
a percentage of the control. *pB/0.05, **pB/0.005; p value
represents the comparison of the effect of IL-1 on IkBb levels
as compared with untreated control (n /4).
FIG. 6. Western blot analysis of cytoplasmic extracts show-
ing the effects of IL-1 treatment (30 ng/ml) on the different
IkB. Inhibition of IkBa and/or IkBb ubiquitination by ZLL
reverses the effects of IL-1. There was no effect of IL-1 on
IkBo levels in Mode-K cells. Expression of IkB was visualized
using speciﬁc polyclonal antibodies. To conﬁrm equal
protein loading the membrane was stripped and reprobed
with actin antibody.
FIG. 7. mRNA levels of the anti-apoptotic proteins bcl-w, bcl-
x, bcl-2 and of pro-apoptotic proteins bak, bax and bad were
measured in IL-1-treated Mode-K cells using the RNA
protection assay.
Regulation of NF-kB by IL-1 and ceramide
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21 In particular, NF-kB has been
shown to modulate the expression of pro-inflamma-
tory cytokines, chemokines, immune receptors, ad-
hesion molecules, and enzymes that generate
mediators of inflammation.
2 Activation of NF-kB
involves the dissociation of the Rel-A (p65) subunit
from inhibitory proteins, mainly IkBa, and its trans-
location from the cytoplasm to the nucleus, where it
dimerizes with the p50 or c-Rel subunits and interacts
with specific target genes. Activation of Rel-A or c-Rel
containing NF-kB dimers results in the transcriptional
stimulation of genes that are important for cell
proliferation. NF-kB also possesses a significant
anti-apoptotic role.
13,14 Indeed, the pro-apoptotic
extracellular signals can also induce NF-kB that in
turn induces the expression of genes that are anti-
apoptotic.
14 We have previously shown that IL-1 and
ceramide did not cause any increase in apoptosis in
Mode-K intestinal epithelial cells.
11 In this report, we
show that treatment of cells with IL-1 caused activa-
tion of NF-kB and that this activation was completely
dependent on its dissociation from the inhibitory
proteins IkBa and IkBb. The release of NF-kB from
IkBb proceeds its dissociation from IkBa.
The increase in the ratio of anti-apoptotic to pro-
apoptotic mRNA provides an explanation for the lack
of induction of apoptosis in IL-1-treated and/or
ceramide-treated IEC. Both stimulators feed into the
prostanoid synthetic pathway through the induction
of COX-2,
11 whhich is thought to be due to activating
NF-kB and translocation Rel-A to the nucleus where it
can then bind on the COX-2 gene and induce its
synthesis.
Mediators that can induce NF-kB could therefore
protect against apoptotic elimination of affected cells.
Interestingly, this anti-apoptotic role of NF-kB has
only been described for Rel-A but not for c-Rel or
p50, which possess pro-apoptotic and anti-prolifera-
tive properties.
14,15 This study shows that, upon
activation of NF-kB, Rel-A was the subunit that was
translocated preferentially from the cytoplasm to the
nucleus, where it is capable of dimerizing with the
p50 or c-Rel subunits and interacts with specific target
genes, some of which are apoptotic proteins. Using
the RNA protection assay we were able to show that
in IL-1-treated or ceramide-treated IEC, the message
levels of anti-apoptotic proteins were significantly
increased while those of the pro-apoptotic proteins
levels were significantly decreased. This correlated
well with what we have observed earlier in IL-1-
treated IEC where it was shown that the protein
levels of bcl-x were increased while protein levels of
bax were significantly reduced.
11 Inhibition of NF-kB
activation and subsequent translocation have been
shown to promote apoptosis in tumor cells such as
multiple myeloma cells.
22 This was achieved using a
proteasome inhibitor PS-341, which prevents the
degradation of IkBs by the proteasomes and hence
the release of NF-kB from the IkB complex. PS-341
has also been recently used in clinical trials to resolve
different types of malignancies.
23,24
Activation of NF-kB is an important event in
numerous inflammatory processes of the gastroin-
testinal tract. Induction of this transcription factor has





Recently, it has been shown that protein kinase C,
intracellular calcium and activation of NF-kB are
crucial for the induction of the COX-2 gene in the
parietal cells in response to carbachol stimulation.
28
Earlier reports have stated that ceramide is a major
second messenger for TNF-a-induced NF-kB activa-
tion,
29,30 while others have not observed any role for
ceramide in IkBa degradation.
31 Ceramide was cap-
able of activating NF-kB to the same extent as IL-1,
providing more evidence that IL-1 causes some of its
effects through the activation of the sphingomyelin
pathway.
10,11 Neither IL-1 nor ceramide induced
apoptosis in IEC but both induced COX-2 synthesis
leading to increased levels of prostaglandin E2.
10,11
The COX-2 gene contains consensus regions for NF-
kB that have been shown to be important for the
induction of COX-2 mRNA levels by cytokines.
12 In
human alveolar epithelial cells,
32 activation of mito-
gen-activated protein kinases by ceramide contri-
butes to the TNF-a signaling that occurs downstream
of neutral sphingomyelinase activation and results in
the stimulation of IkB kinase (IKK1/2) and NF-kBi n
the COX-2 promotor, followed by initiation of COX-2
expression. Pro-inflammatory cytokines activate the
IKK complex that phosphorylates the NF-kB inhibi-
tors, triggering their conjugation with ubiquitin and
subsequent degradation
33,34 via a non-lysosomal,
ATP-dependent proteolytic proteasome. Freed NF-
kB dimers translocate to the nucleus and induce
target genes, such as COX-2, which catalyzes the
synthesis of pro-inflammatory prostaglandins, in
particular prostaglandin E2. At late stages of inflam-
matory episodes, however, COX-2 directs the synth-
esis of anti-inflammatory cyclopentenone prosta-
glandins, suggesting a role for these molecules in
the resolution of inflammation.
ACKNOWLEDGEMENTS. This project is supported by grants from the
American University of Beirut Medical Practice Plan, the Lebanese National
Research Council, and the Third World Academy of Sciences.
References
1. Baldwin AS. The NF-kBa n dI kB proteins: new discoveries and insights.
Annu Rev Immunol 1996; 14: 649 /683.
2. Barnes PJ, Karin M. Nuc1ear factor-kB*/a pivotal transcription factor in
chronic inﬂammatory diseases. N Engl J Med 1997; 336: 1066 /1071.
3. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune
system. Annu Rev lmmunol 1994; 12: 141 /179.
4. Thonas D, Maniatis T. Identiﬁcation of the rel family members required
for virus induction of the human beta interferon gene. Mol Cell Biol
1995; 15: 152 /164.
5. Thonas D, Maniatis T. NF kappa B: a lesson in family values. Cell 1995;
80: 529 /532.
F. R. Homaidan et al.
282 Mediators of Inflammation Vol 12  20036. Finco TS, Baldwin AS. Mechanistic aspects of NF kappa B regulation: the
emerging role of phosphorylation and proteolysis. Immunity 1995; 3:
263 /272.
7. Gilmore TD, Morin PJ. The I-kB proteins: members of a multifunctional
family. Trends Genet 1993; 9:4 2 7 /433.
8. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of
IkB-a proteolysis by site-speciﬁc, signal-induced phosphorylation.
Science 1995; 267:1 4 8 5  /1488.
9. Traenckner EBM, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA.
Phosphorylation of human IkB-a on serines 32 and 36 controls IkB-a
proteolysis and NF-kB activation in response to diverse stimuli. EMBO J
1995; 14: 2876 /2883.
10. Homaidan FR, Chakroun I, Dbaibo GS, El-Assaad W, El-Sabban ME. IL-1
activates two phospholipid signaling pathways in intestinal epithelial
cells. Inﬂamm Res 2001; 50:3 7 5 /381.
11. Homaidan FR, Chakroun I, EJ-Sibai M, Dbaibo GS, EI-Sabban ME. IL-1
stimulates ceramide levels without inducing apoptosis in intestinal
epithelial cells. Mediat Inﬂamm 2002; 11:3 9 /45.
12. Yamamato K, Arakawa T, Ueda N, Yamamato S. Transcriptional role of
nuclear factor kb and nuclear factor interleukin-6 in the tumor necrosis
factor a-dependent induction of cyctoxygenase-2 in MC 3T3-E1 cells. J
Biol Chem 1995; 270: 31315 /31320.
13. Beg AA, Sha WC, Bronson RT, Baltimore D. Embryonic lethality and liver
degeneration in mice lacking the Rel-A component of NF-kappa B.
Nature 1995; 376:1 6 7 /170.
14. Bauerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87:1 3 /
20.
15. Abbadie C, Kaburn N, Boudi F, Smardova J, Stehelin D, Vandenbunder
B, Enrietto PJ. High levels of c-re1 expression are associated with
programmed cell death in the developing avian embryo and in bone
marrow cells in vitro. Cell 1993; 75: 899 /918.
16. Vidal K, Grosjean I, Revillard JP, Gespach C, Kaiserlian D. Immortaliza-
tion of mouse intestinal epithelial cells by SV40-large T gene. Phenotypic
and immune characterization of the Mode-K cell line. J Immunol
Methods 1993; 166:6 3 /73.
17. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresis-
tance in hematologic malignancies. Semin Hematol 1997; 34:9 /19.
18. Mustapha S, Kirshner A, De Moissac D, Kirshenbaum LA. A direct
requirement of nuclear factor-kB for suppression of apoptosis in
ventricular myocytes. Am J Physiol 2000; 279: H939 /H945.
19. Van Atwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of
TNF-k-induced apoptosis by NF-kB. Science 1996; 274: 787 /789.
20. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced
apoptosis: potentiation by inhibition of NF-kB. Science 1996; 274: 784 /
787.
21. Jobin C, Sartor BR. The IkB/NF-kB system: a key determinant of mucosal
inﬂammation and protection. Am J Physiol 2000; 278: C451 /C462.
22. Hideshima T, Mitsiades C, Akiyama, et al. Molecular mechanisms
mediating antimycloma activity of proteasome inhibitor PS-341. Blood
2003; 101: 1530 /1534.
23. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel
proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin
Cancer Res 2002; 8: 2505 /2511.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the
proteasome inhibitor PS-341 in patients with refractory hematologic
malignancies. J Clin Oncol 2002; 20: 4420 /4427.
25. Keates S, Hitti Y, Upton M, Kelly C. Helicobacter pylori infection
activates NF-kB in gastric epithelial cells. Gastroenterology 1997; 113:
1099 /1109.
26. Wahl C, Liptay S, Adler G, Schmid R. Sulfasalazine: a potent and speciﬁc
inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163 /1174.
27. Guvosky I, Guvoskaya A, Blinman T, Zaninovic V, Pandol S. Early NF-kB
activation is associated with hormone-induced pancreatitis. Am J Physiol
1998; 275: G1402 /G1414.
28. Pausawasdi N, Ramamoorthy S, Crofford LJ, Askari FK, Todisco A.
Regulation and function of COX-2 gene expression in isolated gastric
parietal cells. Am J Physiol 2002; 282:G 1 0 6 9 /G1078.
29. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegman K, Kronke M.
TNF activates NF-kB by phosphatidylcholine speciﬁc phospholipase C-
induced ‘acidic’ sphingomyelin breakdown. Cell 1992; 71:7 6 5 /776.
30. Reddy SAG, Chaturvedi M, Darnay BG, Chan H, Higuchi M, Aggarwal
BB. Reconstitution of nuclear factor kB activation induced by tumor
necrosis factor requires membrane-associated components. J Biol Chem
1994; 269: 25369 /25372.
31. Zumbansen M, Stoffel W. Tumor necrosis factor a activates NFkB in acid
sphingomyelinase-deﬁcient mouse embryonic ﬁbroblasts. J Biol Chem
1997; 272: 10904 /10909.
32. Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factor-a-induced
cyclooxygenase-2 expression via sequential activation of ceramide-
dependent mitogen-activated protein kinases, and IkB kinase 1/2 in
human alveolar epithelial cells. Mol Pharmacol 2001; 59:4 9 3 /500.
33. Di Donato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-
responsive IkB kinase that activates the transcription factor NF-kB.
Nature 1997; 388: 548 /554.
34. Zandi E, Chen Y, Karin M. Direct phosphorylation of IkBb yI K K a and
IKKb: discrimination between free and NF-kB-bound substrate. Science
1998; 281: 1360 /1363.
Received 3 June 2003
Accepted 8 August 2003
Regulation of NF-kB by IL-1 and ceramide
Mediators of Inflammation Vol 12  2003 283